- A catalyst is expected for Ironwood, in that it expects an IDMC decision for its phase 3 study IW-3718-302 using IW-3718 to treat patients with refractory GERD Q4 2020.
- The GERD market is expected to be roughly about $4.34 billion by 2025.
- Prescription demand for Linzess was up 9% in Q2 compared to the same time period in 2019; Ironwood has achieved 5 profitable quarters in a row thus far.
- Guidance of 2020 full-year total revenues of Linzess is expected to be between $360 million and $380 million.
For further details see:
Ironwood Is Worth A Look As A Speculative Investment